Psychiatric trials often fail because patients with the same diagnosis can have very different underlying biology. Our molecular signatures let drug developers see those differences, and build trials around them.
Psychiatric clinical trials often fail because patients with the same diagnosis can have very different underlying biology, which makes it hard to identify who is most likely to respond to an investigational therapy. The same signatures that guide clinical decisions let pharmaceutical partners stratify patients by objective molecular profile.
Select participants by molecular profile rather than symptoms alone, so each trial population reflects the biology a therapy is designed to act on.
Biologically consistent cohorts make treatment effects easier to see and increase the likelihood of a successful clinical outcome.
Following regulatory approval, the platform can be deployed as a companion diagnostic, helping clinicians identify the patients most likely to benefit from a specific therapy through a simple blood test.
Every partnership starts from your program's question. A typical collaboration moves through four steps.
Define the question together: the indication, the drug class and the outcome that matters for your program.
We run our molecular signatures on blood samples from your cohort, whether banked from earlier trials or collected at enrollment.
Patients are grouped by molecular profile, and each group is analysed against treatment response and outcomes.
Use the profiles to enrich future trials and, following regulatory approval, co-develop a companion diagnostic.
Whether you're planning a new psychiatric trial or revisiting one that missed its endpoint, we'd like to hear what you're working on.